Mathews CE, Bagley R, Leiter EH: ALS/Lt: a new type 2 diabetes mouse model associated with low free radical scavenging potential. Diabetes 53 (Suppl. 1):S125–S129, 2004
Because it is difficult to distinguish the line graphs in Figs. 2–4 of the above-listed article, the following new figures are provided.
IGT develops early in ALS/Lt males and worsens with age (A). In comparison, males of the closely related ALR/Lt strain do not exhibit glucose intolerance (B).
IGT develops early in ALS/Lt males and worsens with age (A). In comparison, males of the closely related ALR/Lt strain do not exhibit glucose intolerance (B).
ALS/Lt males exhibit insulin resistance. A: Alloxan-treated ALS males show strong resistance to insulin. Alloxan-treated (52 mg/kg) ALS males (solid line) and females (broken line) were treated with 1 unit porcine insulin 7 days after AL administration. One hour later, a blood sample was drawn to test plasma glucose. Figure 3A is the only experiment included in this study where mice were treated with AL. B: ALS/Lt males spontaneously develop hyperinsulinemia and present with insulin resistance as early as 10 weeks of age. Plasma insulin levels were monitored in unmanipulated ALS/Lt and ALR/Lt males from 4 to 52 weeks of age.
ALS/Lt males exhibit insulin resistance. A: Alloxan-treated ALS males show strong resistance to insulin. Alloxan-treated (52 mg/kg) ALS males (solid line) and females (broken line) were treated with 1 unit porcine insulin 7 days after AL administration. One hour later, a blood sample was drawn to test plasma glucose. Figure 3A is the only experiment included in this study where mice were treated with AL. B: ALS/Lt males spontaneously develop hyperinsulinemia and present with insulin resistance as early as 10 weeks of age. Plasma insulin levels were monitored in unmanipulated ALS/Lt and ALR/Lt males from 4 to 52 weeks of age.
Daily LA treatment of ALS/Lt males inhibits progression of type 2 diabetes, reducing body weight (A), plasma glucose levels (B), and increasing the levels of circulating reduced GSH (C). Ten ALS/Lt males were randomized into two groups (n = 5 per group) either receiving 30 mg/kg of LA (dashed line) or vehicle alone (solid line). Over the following 8 weeks, significant differences were measured at both 14 and 18 weeks of age in plasma glucose and reduced GSH concentrations (P < 0.05).
Daily LA treatment of ALS/Lt males inhibits progression of type 2 diabetes, reducing body weight (A), plasma glucose levels (B), and increasing the levels of circulating reduced GSH (C). Ten ALS/Lt males were randomized into two groups (n = 5 per group) either receiving 30 mg/kg of LA (dashed line) or vehicle alone (solid line). Over the following 8 weeks, significant differences were measured at both 14 and 18 weeks of age in plasma glucose and reduced GSH concentrations (P < 0.05).
